S&P 500   3,225.89 (-3.35%)
DOW   27,960.80 (-3.56%)
QQQ   221.39 (-3.86%)
AAPL   298.18 (-4.75%)
FB   200.72 (-4.50%)
MSFT   170.89 (-4.31%)
GOOGL   1,419.86 (-4.29%)
AMZN   2,009.29 (-4.14%)
CGC   20.30 (-7.22%)
NVDA   273.28 (-7.07%)
BABA   206.16 (-3.02%)
MU   55.01 (-3.47%)
GE   11.86 (-3.18%)
TSLA   833.79 (-7.46%)
AMD   49.12 (-7.81%)
T   38.05 (-1.30%)
ACB   1.55 (-7.19%)
F   7.57 (-4.06%)
NFLX   368.70 (-2.99%)
PRI   126.97 (-4.05%)
BAC   32.73 (-4.74%)
DIS   133.01 (-4.29%)
GILD   72.90 (+4.59%)
S&P 500   3,225.89 (-3.35%)
DOW   27,960.80 (-3.56%)
QQQ   221.39 (-3.86%)
AAPL   298.18 (-4.75%)
FB   200.72 (-4.50%)
MSFT   170.89 (-4.31%)
GOOGL   1,419.86 (-4.29%)
AMZN   2,009.29 (-4.14%)
CGC   20.30 (-7.22%)
NVDA   273.28 (-7.07%)
BABA   206.16 (-3.02%)
MU   55.01 (-3.47%)
GE   11.86 (-3.18%)
TSLA   833.79 (-7.46%)
AMD   49.12 (-7.81%)
T   38.05 (-1.30%)
ACB   1.55 (-7.19%)
F   7.57 (-4.06%)
NFLX   368.70 (-2.99%)
PRI   126.97 (-4.05%)
BAC   32.73 (-4.74%)
DIS   133.01 (-4.29%)
GILD   72.90 (+4.59%)
S&P 500   3,225.89 (-3.35%)
DOW   27,960.80 (-3.56%)
QQQ   221.39 (-3.86%)
AAPL   298.18 (-4.75%)
FB   200.72 (-4.50%)
MSFT   170.89 (-4.31%)
GOOGL   1,419.86 (-4.29%)
AMZN   2,009.29 (-4.14%)
CGC   20.30 (-7.22%)
NVDA   273.28 (-7.07%)
BABA   206.16 (-3.02%)
MU   55.01 (-3.47%)
GE   11.86 (-3.18%)
TSLA   833.79 (-7.46%)
AMD   49.12 (-7.81%)
T   38.05 (-1.30%)
ACB   1.55 (-7.19%)
F   7.57 (-4.06%)
NFLX   368.70 (-2.99%)
PRI   126.97 (-4.05%)
BAC   32.73 (-4.74%)
DIS   133.01 (-4.29%)
GILD   72.90 (+4.59%)
S&P 500   3,225.89 (-3.35%)
DOW   27,960.80 (-3.56%)
QQQ   221.39 (-3.86%)
AAPL   298.18 (-4.75%)
FB   200.72 (-4.50%)
MSFT   170.89 (-4.31%)
GOOGL   1,419.86 (-4.29%)
AMZN   2,009.29 (-4.14%)
CGC   20.30 (-7.22%)
NVDA   273.28 (-7.07%)
BABA   206.16 (-3.02%)
MU   55.01 (-3.47%)
GE   11.86 (-3.18%)
TSLA   833.79 (-7.46%)
AMD   49.12 (-7.81%)
T   38.05 (-1.30%)
ACB   1.55 (-7.19%)
F   7.57 (-4.06%)
NFLX   368.70 (-2.99%)
PRI   126.97 (-4.05%)
BAC   32.73 (-4.74%)
DIS   133.01 (-4.29%)
GILD   72.90 (+4.59%)
Log in

NASDAQ:KURA - Kura Oncology Stock Price, Forecast & News

$12.55
-0.05 (-0.40 %)
(As of 02/24/2020 04:00 PM ET)
Today's Range
$12.16
Now: $12.55
$12.55
50-Day Range
$11.69
MA: $12.46
$13.90
52-Week Range
$11.41
Now: $12.55
$21.42
Volume311,200 shs
Average Volume258,544 shs
Market Capitalization$568.70 million
P/E RatioN/A
Dividend YieldN/A
Beta2.53
Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidate is Tipifarnib, an oral farnesyl transferase inhibitor that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:KURA
CUSIPN/A
Phone858-500-8800

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$4.22 per share

Profitability

Net Income$-60,450,000.00

Miscellaneous

Employees43
Market Cap$568.70 million
Next Earnings Date2/25/2020 (Confirmed)
OptionableOptionable

Receive KURA News and Ratings via Email

Sign-up to receive the latest news and ratings for KURA and its competitors with MarketBeat's FREE daily newsletter.


Kura Oncology (NASDAQ:KURA) Frequently Asked Questions

What is Kura Oncology's stock symbol?

Kura Oncology trades on the NASDAQ under the ticker symbol "KURA."

How were Kura Oncology's earnings last quarter?

Kura Oncology Inc (NASDAQ:KURA) issued its earnings results on Tuesday, November, 5th. The company reported ($0.36) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.39) by $0.03. View Kura Oncology's Earnings History.

When is Kura Oncology's next earnings date?

Kura Oncology is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for Kura Oncology.

How can I listen to Kura Oncology's earnings call?

Kura Oncology will be holding an earnings conference call on Tuesday, February 25th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

What price target have analysts set for KURA?

8 brokerages have issued 12-month price objectives for Kura Oncology's shares. Their forecasts range from $22.00 to $30.00. On average, they anticipate Kura Oncology's stock price to reach $26.83 in the next year. This suggests a possible upside of 113.8% from the stock's current price. View Analyst Price Targets for Kura Oncology.

What is the consensus analysts' recommendation for Kura Oncology?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kura Oncology in the last year. There are currently 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Kura Oncology.

Has Kura Oncology been receiving favorable news coverage?

Media coverage about KURA stock has been trending neutral recently, according to InfoTrie Sentiment. The research group rates the sentiment of press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Kura Oncology earned a media sentiment score of 0.4 on InfoTrie's scale. They also gave news stories about the company a news buzz of 9.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the company's share price in the next several days. View News Stories for Kura Oncology.

Are investors shorting Kura Oncology?

Kura Oncology saw a increase in short interest in the month of January. As of January 31st, there was short interest totalling 2,530,000 shares, an increase of 26.5% from the January 15th total of 2,000,000 shares. Based on an average daily volume of 293,700 shares, the short-interest ratio is currently 8.6 days. Currently, 6.2% of the company's shares are sold short. View Kura Oncology's Current Options Chain.

Who are some of Kura Oncology's key competitors?

What other stocks do shareholders of Kura Oncology own?

Who are Kura Oncology's key executives?

Kura Oncology's management team includes the folowing people:
  • Dr. Troy Edward Wilson, Chairman, CEO & Pres (Age 50)
  • Dr. Antonio Gualberto, Head of Devel. & Chief Medical Officer (Age 54)
  • Dr. Marc Grasso, CFO & Chief Bus. Officer
  • Mr. John Farnam, Chief Operating Officer
  • Mr. Pete De Spain, VP of Investor Relations & Corp. Communications

Who are Kura Oncology's major shareholders?

Kura Oncology's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include FMR LLC (15.00%), EcoR1 Capital LLC (9.36%), Victory Capital Management Inc. (5.26%), Victory Capital Management Inc. (5.24%), Eagle Asset Management Inc. (4.55%) and State Street Corp (2.34%). Company insiders that own Kura Oncology stock include Antonio Gualberto and Ecor1 Capital Fund Qualified,. View Institutional Ownership Trends for Kura Oncology.

Which major investors are selling Kura Oncology stock?

KURA stock was sold by a variety of institutional investors in the last quarter, including Arch Venture Corp, Driehaus Capital Management LLC, State Street Corp, Man Group plc, SG Americas Securities LLC, Oak Ridge Investments LLC, UBS Group AG and Rafferty Asset Management LLC. View Insider Buying and Selling for Kura Oncology.

Which major investors are buying Kura Oncology stock?

KURA stock was acquired by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., EcoR1 Capital LLC, Point72 Asset Management L.P., WCM Investment Management LLC, Victory Capital Management Inc., Victory Capital Management Inc., FMR LLC and Pathway Capital Management LP. View Insider Buying and Selling for Kura Oncology.

How do I buy shares of Kura Oncology?

Shares of KURA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Kura Oncology's stock price today?

One share of KURA stock can currently be purchased for approximately $12.55.

How big of a company is Kura Oncology?

Kura Oncology has a market capitalization of $568.70 million. The company earns $-60,450,000.00 in net income (profit) each year or ($1.72) on an earnings per share basis. Kura Oncology employs 43 workers across the globe.View Additional Information About Kura Oncology.

What is Kura Oncology's official website?

The official website for Kura Oncology is http://www.kuraoncology.com/.

How can I contact Kura Oncology?

Kura Oncology's mailing address is 3033 SCIENCE PARK ROAD SUITE 220, SAN DIEGO CA, 92121. The company can be reached via phone at 858-500-8800 or via email at [email protected]


MarketBeat Community Rating for Kura Oncology (NASDAQ KURA)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  317 (Vote Outperform)
Underperform Votes:  283 (Vote Underperform)
Total Votes:  600
MarketBeat's community ratings are surveys of what our community members think about Kura Oncology and other stocks. Vote "Outperform" if you believe KURA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KURA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/24/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel